A Comprehensive Meta-Analysis of Pharmacological Interventions for Rheumatoid Arthritis: Efficacy and Safety Profile
Keywords:
RA, PGA, Pharmacological intervention, Inhibitors, Safety, Meta-AnalysisAbstract
Efficacious pharmacological intervention is required in the management of rheumatoid arthritis (RA); thus, it is a comprehensive autoimmune arthritis disorder causing synovial inflammation and joint damage. This meta-analysis evaluates the efficacy and safety profiles of csDMARDs, bDMARDs, tsDMARDs, and Stephania Tetrandra Derivatives based on a systematic review of five studies (2008- 2025; n = 6,800 patients). Included were RCTs, observational studies, and meta-analyses from PubMed, Embase, and the Cochrane Library, focusing on outcomes such as DPS28 remission, HAQ-DI scores, and adverse events in which csDMARDs (e.g., PGA): Achieved DAS28 remission in 40% to 50% of early RA patients.
In bDMARDs (e.g., TNF and IL-6 inhibitors), this was almost 60% to 70% in refractory RA for low disease activity. While PGA remains first-line for early RA, biologics are best for refractory disease. JAK inhibitors should be used cautiously in those at moderate to high risk. Pharmacological Interventions do appear to have some advantages and reduced GI side effects, warranting further studies on using it as an adjunct and. This synthesis delineates the trade-off between efficacy and safety in RA therapeutics, thereby advocating regimen selections according to risk factors unique to the patient.
References
Conforti A., di Cola I., Pavlych V., Ruscitti P., Berardicurti O., Ursini F., Giacomelli R., Cipriani P. Beyond the joints, the extra-articular manifestations in rheumatoid arthritis. Autoimmun. Rev. 2021;20:102735. doi: 10.1016/j.autrev.2020.102735. [DOI] [PubMed] [Google Scholar]
Cojocaru M., Cojocaru I.M., Silosi I., Vrabie C.D., Tanasescu R. Extra-articular manifestations in rheumatoid arthritis. Mædica. 2010;5:286–291. [PMC free article] [PubMed] [Google Scholar]
Joseph A., Brasington R., Kahl L., Ranganathan P., Cheng T.P., Atkinson J. Immunologic rheumatic disorders. J. Allergy Clin. Immunol. 2010;125:S204–S215. doi: 10.1016/j.jaci.2009.10.067. [DOI] [PubMed] [Google Scholar]
Kurowska W., Kuca-Warnawin E.H., Radzikowska A., Maśliński W. The role of anti-citrullinated protein antibodies (ACPA) in the pathogenesis of rheumatoid arthritis. Cent. J. Immunol. 2017;42:390–398. doi: 10.5114/ceji.2017.72807. [DOI] [PMC free article] [PubMed] [Google Scholar]
Wegner N., Lundberg K., Kinloch A., Fisher B., Malmström V., Feldmann M., Venables P.J. Autoimmunity to specific citrullinated proteins gives the first clues to the etiology of rheumatoid arthritis. Immunol. Rev. 2010;233:34–54. doi: 10.1111/j.0105-2896.2009.00850.x. [DOI] [PubMed] [Google Scholar]
Chaurasia N., Singh A., Singh I.L., Singh T., Tiwari T. Cognitive dysfunction in patients of rheumatoid arthritis. J. Fam. Med. Prim. Care. 2020;9:2219–2225. Doi: 10.4103/jfmpc.jfmpc_307_20. [DOI] [PMC free article] [PubMed] [Google Scholar]
Lassere M.N., Rappo J., Portek I.J., Sturgess A., Edmonds J.P. How many life years are lost in patients with rheumatoid arthritis? Secular cause-specific and all-cause mortality in rheumatoid arthritis, and their predictors in a long-term Australian cohort study. Intern. Med. J. 2013;43:66–72. doi: 10.1111/j.1445-5994.2012.02727.x. [DOI] [PubMed] [Google Scholar]
Genovese M., McKay J., Nasonov E., Mysler E., da Silva N., Alecock E., et al. (2008) Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: the tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study. Arthritis Rheum 58: 2968–2980 [DOI] [PubMed] [Google Scholar]
Harris E., Jr(1990) Rheumatoid arthritis. Pathophysiology and implications for therapy. N Engl J Med 322: 1277–1289 [DOI] [PubMed] [Google Scholar]
Hyrich K., Lunt M., Watson K., Symmons D., Silman A.; British Society for Rheumatology Biologics Register (2007) Outcomes after switching from one anti-tumor necrosis factor alpha agent to a second anti-tumor necrosis factor alpha agent in patients with rheumatoid arthritis: results from a large UK national cohort study. Arthritis Rheum 56: 13–20 [DOI] [PubMed] [Google Scholar]
Jones G., Sebba A., Gu J., Lowenstein M., Calvo A., Gomez-Reino J., et al. (2010) Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study. Ann Rheum Dis 69: 88–96 [DOI] [PMC free article] [PubMed] [Google Scholar]
Kaneko A., Kida D., Saito K., Tsukamoto M., Sato T. (2011) Clinical results for tocilizumab over one year in the clinical setting as assessed by CDAI (clinical disease activity index): CRP at week 12 and MMP-3 at week 24 are predictive factors for CDAI. Rheumatol Int 30 November (Epub ahead of print). DOI: 10.1007/s00296-011-2256-5 [DOI] [PubMed] [Google Scholar]
Karlsson J., Kristensen L., Kapetanovic M., Gülfe A., Saxne T., Geborek P. (2008) Treatment response to a second or third TNF-inhibitor in RA: results from the South Swedish Arthritis Treatment Group Register. Rheumatology (Oxford) 47: 507–513 [DOI] [PubMed] [Google Scholar]
Burmester G.R., Kremer J.M., Bosch F.V.D., Kivitz A., Bessette L., Li Y., Zhou Y., Othman A.A., Pangan A.L., Camp H.S. Safety and efficacy of upadacitinib in patients with rheumatoid arthritis and inadequate response to conventional synthetic disease-modifying anti-rheumatic drugs (SELECT-NEXT): A randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2018;391:2503–2512. doi: 10.1016/S0140-6736 (18)31115-2. [DOI] [PubMed] [Google Scholar]
Genovese M.C., Fleischmann R., Combe B., Hall S., Rubbert-Roth A., Zhang Y., Zhou Y., Mohamed M.-E.F., Meerwein S., Pangan A.L. Safety and efficacy of upadacitinib in patients with active rheumatoid arthritis refractory to biologic disease-modifying anti-rheumatic drugs (SELECT- BEYOND): A double-blind, randomised controlled phase 3 trial. Lancet. 2018;391:2513–2524. doi: 10.1016/S0140-6736 (18)31116-4. [DOI] [PubMed] [Google Scholar]
Fleischmann R.M., Genovese M.C., Enejosa J.V., Mysler E., Bessette L., Peterfy C., Durez P., Ostor A., Li Y., Song I.-H. Safety and efectiveness of upadacitinib or adalimumab plus methotrexate in patients with rheumatoid arthritis over 48 weeks with a switch to alternate therapy in patients with insufficient response. Ann. Rheum. Dis. 2019;78:1454–1462. doi: 10.1136/annrheumdis-2019-215764. [DOI] [PMC free article] [PubMed] [Google Scholar]
Fleischmann R., Pangan A.L., Song I., Mysler E., Bessette L., Peterfy C., Durez P., Ostor A.J., Li Y., Zhou Y., et al. Upadacitinib versus placebo or adalimumab in patients with rheumatoid arthritis and an inadequate response to methotrexate: Results of phase III, Beneft–Risk Profle of Upadacitinib in Rheumatoid Arthritis 529 double-blind, randomized controlled trial. Arthritis Rheumatol. 2019;71:1788–1800. doi: 10.1002/art.41032. [DOI] [PubMed] [Google Scholar]
Burmester G.R., Bosch F.v.D., Bessette L., Kivitz A., Yihan L., Friedman A., Pangan A., Camp H., Kremer J. Long-term safety and efficacy of upadacitinib in patients with rheumatoid arthritis and an inadequate response to csDMARDs: Results at 60 weeks from the SELECT-NEXT study. Ann. Rheum. Dis. 2019;78:735–736. doi: 10.1136/annrheumdis-2019-eular.3082. [DOI] [Google Scholar]
Smolen J.S., Pangan A.L., Emery P., Rigby W., Tanaka Y., Vargas J.I., Zhang Y., Damjanov N., Friedman A., Othman A.A., et al. Upadacitinib as monotherapy in patients with active rheumatoid arthritis and inadequate response to methotrexate (SELECT-MONOTHERAPY): A randomized, placebo-controlled, double-blind phase 3 study. Lancet. 2019;393:2303–2311. doi: 10.1016/S0140-6736 (19)30419-2. [DOI] [PubMed] [Google Scholar]
van Vollenhoven R., Takeuchi T., Pangan A.L., Friedman A., Mohamed M.F., Chen S., Rischmueller M., Blanco R., Xavier R.M., Strand V. Efficacy and safety of upadacitinib monotherapy in methotrexate-naïve patients with moderately to severely active rheumatoid arthritis (SELECT-EARLY): A randomized, double-blind, active-comparator, multi-center, multi-country trial. Arthritis Rheumatol. 2020;72:1607–1620. doi: 10.1002/art.41384
